Cullgen

Cullgen is a clinical-stage biotechnology company pioneering a next-generation targeted protein degradation platform called uSMITE™ to drug traditionally 'undruggable' targets. The company has advanced programs into Phase 1 clinical trials, including a non-opioid candidate for pain, and is developing Degrader-Antibody Conjugates (DACs) as a novel therapeutic modality. In March 2026, Gyre Therapeutics entered into an agreement to acquire Cullgen, highlighting the strategic value of its platform and pipeline. Cullgen's approach aims to expand the drug design paradigm for oncology, pain, and inflammation.

Proprietary uSMITE™ platform for targeted protein degradation, featuring novel E3 ligase ligands for creating heterobifunctional degraders and Degrader-Antibody Conjugates (DACs).

Cullgen operates in the highly competitive targeted protein degradation space, competing with public companies like Arvinas, Nurix, and Kymera, as well as numerous biotech startups and large pharmaceutical firms with internal TPD efforts. Its differentiation relies on its proprietary E3 ligase ligands and DAC platform.